相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
4°C, sealed storage, away from moisture and light
- 英文名:
PTK 0796 mesylate; Amadacycline mesylate
- 库存:
货期:电询
- 供应商:
MedChemExpress LLC
- CAS号:
1196800-40-4
- 规格:
电询
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Omadacycline mesylate
CAS No. : 1196800-40-4
MCE 国际站:Omadacycline mesylate
产品活性:Omadacycline (PTK 0796) mesylate,首创的具有口服活性的氨基甲基环素抗菌剂,是一种四环素类抗生素。Omadacycline mesylate 通过与 30S 核糖体亚基结合来抑制细菌蛋白质的合成。Omadacycline mesylate 对多种细菌表现出活性,包括好氧和厌氧革兰氏阳性细菌和革兰氏阴性细菌,非典型病原体。Omadacycline mesylate 可用于研究急性细菌性皮肤和皮肤结构感染,感染性肺炎和尿路感染。
研究领域:Anti-infection
作用靶点:Bacterial | Antibiotic
In Vitro: Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae), with MIC90s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively.
Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux.
In Vivo: Omadacycline (0.11-18 mg/kg; a single i.v.) exhibits efficacy against Streptococcus pneumonia, Escherichia coli, and Staphylococcus aureus in mice systemic infection model, with ED50s ranging from 0.30 mg/kg to 3.39 mg/kg.
相关产品:Rapamycin | Cycloheximide | Chloroquine | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Puromycin dihydrochloride | Dimethyl sulfoxide | Staurosporine | Actinomycin D | G-418 disulfate | Etoposide | 5-Azacytidine | Cyclosporin A | Nigericin sodium salt | Brefeldin A | Estradiol | CCCP | Ionomycin | Resveratrol | Hygromycin B | Tunicamycin | Bleomycin sulfate | Mitomycin C | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Wortmannin
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
-4 and C-5 centers ( 3 ). After formatron of the mesylate, from the recycled material the amine function is introduced through azrde displacement of the mesylate, followed by reduction ( 4 ) and protectron with the t -BOC group. Finally, the lactone
Treatment of Infections Due to Resistant Staphylococcus aureus
with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid
技术资料暂无技术资料 索取技术资料

















